Aspen Pharmacare

What Aspen Pharmacare does

Aspen Pharmacare Holdings Limited is a Johannesburg-listed (JSE: APN) global specialty and branded multinational pharmaceutical company headquartered in Durban, South Africa, with operating heritage tracing back to 1850 through Lennon Ltd and a modern corporate origin in 1997 under founding shareholders Stephen Saad and Gus Attridge. The company manufactures and markets prescription, over-the-counter and injectable medicines across four reporting segments — Prescription (29% of group revenue), OTC (22%), Injectables (23%), and Manufacturing (26%) — and operates 24 manufacturing facilities across 15 sites with approvals from US FDA, Australian TGA, and the European Directorate for the Quality of Medicines. Its commercial reach spans 115+ countries through 66 established offices in over 48 countries, with regional hubs in Africa Middle East, Americas, Asia (notably >600 headcount in China), Australasia, and Europe CIS.

The product portfolio combines acquired multinational IP (AstraZeneca anaesthetics in 100 countries, GSK's Eltroxin/Imuran/Lanoxin/Zyloric and Arixtra/Fraxiparine thrombolytics, Sandoz's Sandostatin, Viatris ex-US portfolio, the Mounjaro distribution agreement with Eli Lilly) with emerging-market brands (Aspenovax COVID-19 vaccine, Aspen Stavudine, Maltofer, Ovestin) and a growing specialty metabolic franchise around GLP-1 therapies (Mounjaro at 41% SA value share and a targeted generic semaglutide program). Manufacturing capabilities span steriles, oral solid dose, liquids, semi-solids, biologicals and APIs, and Aspen produced over 225 million doses of J&J's COVID-19 vaccine at its Gqeberha facility.

Revenue is generated principally through prescription product sales, OTC distribution via retail pharmacy and FMCG channels, hospital injectable supply, and contract manufacturing services to third parties, with public-sector tenders (ARVs, vaccines) and government health departments as a key institutional channel. H1 FY2026 revenue was R21.1 billion (~$1.3 billion, down 4.1% YoY), implying a pre-divestment FY2025 run-rate around R43.6 billion; the December 2025 sale of the Asia Pacific business (ex-China) to BGH Capital for R26.5 billion (~$1.6 billion, ~11x normalized EBITDA) completed in May 2026 and leaves the group largely debt-free.

Name

Aspen Pharmacare

Legal name

Aspen Pharmacare Holdings Limited

Website

https://aspenpharma.com

Company type

Public

Founded year

1997

Operating status

Operating

Headcount range

1,001–5,000 employees

Short description

Aspen Pharmacare is a South Africa-headquartered, JSE-listed global pharmaceutical company that manufactures and distributes branded and generic prescription, OTC, and injectable medicines across 115+ countries via 24 manufacturing facilities and a 66-office commercial network.

Ownership category

akta.pro rank

Product category

Specialty Pharmaceuticals

NAICS

Pharmaceutical Preparation Manufacturing (325412), Pharmaceutical and Medicine Manufacturing (3254)

SIC

Pharmaceutical Preparations (2834), Wholesale-Drugs, Proprietaries & Druggists' Sundries (5122), Medicinal Chemicals & Botanical Products (2833)

akta.pro primary industry

Government & Public-Sector Pharmaceutical Supply (Tender/Prime Vendor) (HLAIAJAF)

akta.pro secondary industries

Vaccines & Cold-Chain Pharmaceutical Distributors (HLAIAJAG), Vaccine Cold Chain, Storage & Distribution (HLAIAEAK), Third-Party Logistics (3PL) & Warehousing for Pharmaceuticals (HLAIAJAL), Public Health Contracts, Procurement & Vendor Management (HLAJALAE)

Keywords

• Generic pharmaceuticals
• Branded pharmaceutical products
• Active pharmaceutical ingredients
• Sterile injectable manufacturing
• Over-the-counter medicines

Headquarters

HQ city

Durban

HQ country

South Africa

HQ region

Africa

Offices17 records

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Operations, Supply Chain, Personnel, Technology or R&D, Infrastructure, Marketing or Sales

Revenue model

1. Commercial Pharmaceuticals: Revenue from marketing and selling prescription medicines, OTC products, and injectables across global markets. Accounts for majority of group revenue with operations in Africa, Americas, Asia, Australasia, and Europe CIS.
2. Manufacturing: Revenue from manufacturing finished dose form products, active pharmaceutical ingredients, and heparin for third-party customers and internal use. 24 manufacturing facilities across 15 sites.
3. Prescription Segment: Products requiring prescription including anti-inflammatories, immunosuppressants, hypothyroidism treatments, anti-gout, analgesics, and corticosteroids. Contributed 29% of group revenue.
4. Over the Counter Segment: Products sold without prescription through retail pharmacies and FMCG sector. Includes topical anesthetics, iron supplements, antacids, analgesics, and hormone replacement therapy.
5. Injectables Segment: Hospital-administered products focusing on anesthetics, anticoagulants, antithrombotic agents, analgesics, and hormone replacement therapies. Contributed 23% of group revenue.

Go-to-market motion4 records

Distribution channels6 records

Marketing channels5 records

Core offering

Aspen Pharmacare is a global specialty and branded multinational pharmaceutical company that develops, manufactures, and distributes prescription medicines, over-the-counter consumer health products, hospital injectables, and active pharmaceutical ingredients across more than 115 countries. The group operates 24 manufacturing facilities across 15 sites producing steriles, oral solid doses, liquids, semi-solids, biologicals, and APIs under international regulatory approvals from the US FDA, Australian TGA, and European EDQM. Beyond proprietary brands, Aspen generates third-party contract manufacturing revenue and partners with multinational pharma companies for in-licensed and out-licensed products such as Eli Lilly's Mounjaro and Johnson & Johnson's COVID-19 vaccine (Aspenovax).

Product overview

Aspen Pharmacare is a global specialty and branded multinational pharmaceutical company with four key business segments: Prescription (29% of group revenue), Over the Counter (22%), Injectables (23%), and Manufacturing (26%). The company markets and manufactures a broad portfolio of post-patent, branded medicines and domestic brands covering hospital and consumer markets. Key products include Mounjaro (GLP-1 diabetes/weight-loss drug), Eltroxin (thyroid hormone), Imuran (immunosuppressant), Lipitor (statin), and injectable anesthetics (Xylocaine, Diprivan), anticoagulants (Arixtra, Fraxiparine). Manufacturing capabilities span steriles, oral solid doses, liquids, semi-solids, biologicals, and active pharmaceutical ingredients across 24 facilities in 15 sites globally.

Differentiator

Problem solved

Functional benefit

Brands

• Mounjaro: GLP-1 agonist for diabetes and weight loss management, distributed in South Africa by Aspen under Eli Lilly partnership
• Aspenovax
• Eltroxin
• Imuran
• Lipitor
• Sandostatin
• Arixtra
• Fraxiparine
• Diprivan
• Xylocaine
• Solpadeine

Products and services

• Mounjaro (Tirzepatide)

Quantifiable outcome

• 225+ million COVID-19 vaccine doses manufactured at Gqeberha facility
• +5 more outcomes

Named customers5 records

Segments5 records

Ideal customer profiles3 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature4 records

Partnerships

Ten partnerships are on record, tiered core and minor.

• Africa CDC (Africa Centres for Disease Control and Prevention)coreStrategic or Co-development Partner · 12 May 2026Advanced discussions on long-term demand and supply framework for vaccines produced in Africa. Proposed multi-year procurement framework would commit African countries to purchasing locally produced vaccines with potential volumes scaling to hundreds of millions of doses annually.
• Eli Lilly and CompanycoreChannel Partner/ Reseller/ Distributor · 4 March 2026Aspen pursuing approval for Mounjaro in sub-Saharan Africa and distributing the drug in South Africa. Mounjaro became fastest product to reach R100 million in SA pharmaceutical history. Aspen aims to become key regional manufacturer and distributor of GLP-1 injectables.
• Gilead SciencesminorChannel Partner/ Reseller/ Distributor · 1 January 2026South African government engaging with Gilead to identify local manufacturers for lenacapavir (HIV prevention shot) under voluntary license. Aspen has warned that guaranteed demand is necessary for local production but no South African firm has been awarded licenses.
• Serum Institute of IndiacoreStrategic or Co-development Partner · 1 January 2022Technology transfer agreement for manufacturing four routine vaccines in Africa. Part of ten-year initiative to improve vaccine supply, affordability, and health security across Africa, supported by Gates Foundation and CEPI funding.
• GlaxoSmithKline (GSK)coreStrategic or Co-development PartnerProven track record of growing multinational partnerships. Acquired intellectual property rights from GSK for four key global brands (Eltroxin, Imuran, Lanoxin, Zyloric) and acquired Arixtra and Fraxiparine thrombolytic brands worldwide plus sterile production site in France.
• Amgen, Vifor, Bayer, Roche, Boehringer IngelheimcoreChannel Partner/ Reseller/ DistributorLong-term distribution and promotional agreements with leading multinational pharmaceutical companies including Amgen, Vifor, Bayer, Roche, and recently Boehringer Ingelheim.
• AstraZenecacoreStrategic or Co-development PartnerAcquired exclusive rights to commercialize AstraZeneca's global anaesthetics portfolio in 100 countries (including China, excluding USA). Later acquired remaining IP and manufacturing know-how for the portfolio.
• Johnson & JohnsoncoreStrategic or Co-development PartnerManufactured over 225 million doses of J&J COVID-19 vaccine at Gqeberha facility. Concluded agreement for manufacture and sale of Aspen-branded COVID-19 vaccine (Aspenovax) to public sector markets in Africa.
• Pharmaceutical Supply Chain Initiative (PSCI)minorStrategic or Co-development PartnerParticipation in industry collaboration improving supply chain environmental, social and governance (ESG) practices.
• UN Global CompactminorStrategic or Co-development PartnerAspen is a participant of the UN Global Compact, committed to upholding principles of respecting and protecting internationally proclaimed human rights.

Scale indicators15 records

Recent moves8 records

Expansion highlights6 records

Direct peers

• Cipla: Indian-headquartered global pharmaceutical company with deep presence in Africa and emerging markets, strong generics franchise, and leadership in respiratory, antiretroviral, and complex generics — directly comparable to Aspen's emerging-markets generics and ARV platform.
• Aurobindo Pharma: Indian global generics manufacturer with significant ARV production, US FDA-approved facilities, and broad emerging-markets distribution — closely comparable to Aspen's generics manufacturing scale and ARV/government supply profile.
• Viatris: Global generics and specialty pharma company formed via Mylan-Upjohn combination; counterparty in Aspen's Viatris portfolio acquisition and highly comparable in product mix, geographic reach, and emerging-market positioning.
• Dr. Reddy's Laboratories: Indian-headquartered global pharmaceutical company with strong generics, API, and biosimilars franchises across emerging and developed markets — closely comparable to Aspen's manufacturing-plus-distribution model.
• Sun Pharmaceutical Industries: India's largest pharmaceutical company by revenue with global generics, specialty, and API operations; comparable in scale, regulatory footprint, and emerging-market commercial reach to Aspen.
• Strides Pharma Science: Indian-headquartered generics manufacturer with explicit Africa focus, soft-gel and complex generics capabilities, and regulated-market approvals — comparable to Aspen's emerging-market specialty generics positioning.

Broad incumbents

• Teva Pharmaceutical Industries: World's largest generics manufacturer with extensive specialty and biosimilars portfolio — comparable as a broad incumbent in the same generics and specialty pharma space, though far larger and more diversified than Aspen.
• Sanofi: Global pharmaceutical leader with deep emerging-markets presence, generics/specialty portfolio, and consumer healthcare franchise — broad incumbent comparable in geographic and therapeutic diversification, though larger and more diversified than Aspen.
• Novartis: Global pharmaceutical major with significant emerging-market presence through Sandoz generics division (Aspen acquired Sandoz's China business for $100M). Comparable as broad incumbent with generics/specialty exposure in markets where Aspen competes.

Others

• GSK: Global pharmaceutical major and long-term Aspen partner (Anaesthetics portfolio acquired, thrombolytic brands, distribution rights). Comparable as a key counterparty whose IP and partnerships have shaped Aspen's portfolio strategy.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat6 records

Key risks6 records

Key highlights7 records

Customer concentration

• Xx.com/aspenpharma
• Facebookweb.facebook.com/aspenpharma
• LinkedInlinkedin.com/company/41810
• Instagraminstagram.com/aspenpharma1

Compliance8 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles19 records

Subsidiaries13 records

Funding overview

Funding rounds2 records

Investors2 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Aspen Pharmacare